Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
dc.contributor.author | Ebenhan, Thomas![]() |
|
dc.contributor.author | Zeevaart, Jan Rijn![]() |
|
dc.contributor.author | Venter, Jacobus D.![]() |
|
dc.contributor.author | Govender, Thavendran![]() |
|
dc.contributor.author | Kruger, Gert H.![]() |
|
dc.contributor.author | Jarvis, Neil V.![]() |
|
dc.contributor.author | Sathekge, Mike Machaba![]() |
|
dc.date.accessioned | 2014-08-19T08:47:02Z | |
dc.date.available | 2014-08-19T08:47:02Z | |
dc.date.issued | 2014-02 | |
dc.description.abstract | Antimicrobial peptides such as ubiquicidin (UBI) are believed to differentiate between mammalian and bacterial or fungal cells. (99m)Tc-UBI29-41 was previously tested for detecting infection in humans using SPECT. For the present study, the UBI fragment UBI29-41 (TGRAKRRMQYNRR) was conjugated to 1,4,7-triazacyclononane-triacetic acid (NOTA), radiolabeled with (68)Ga, and investigated in a rabbit infection model. METHODS : (68)Ga was obtained from a 1.85-GBq (68)Ge/(68)Ga generator. New Zealand White rabbits were anesthetized with ketamine/medetomidine before tracer administration and placed in a clinical PET/CT scanner. (68)Ga-1,4,7-triazacyclononane-1,4,7-triacetic-acid-ubiquicidin29-41 ((68)Ga-NOTA-UBI29-41) was formulated in saline solution, and 101 ± 41 MBq were administered intravenously. The tracer distribution was studied by PET/CT imaging in animals (a) that were healthy, (b) bearing muscular Staphylococcus aureus infections and turpentine oil-induced muscular inflammations, and (c) bearing ovalbumin-induced lung inflammations. Static PET/CT imaging was performed at different time intervals up to 120 min after injection. For calculation of target-to-nontarget ratios, standardized uptake values were normalized against healthy thigh muscle, representing nontargeted tissue. RESULTS : PET/CT images of healthy animals showed predominant distribution in the kidneys, liver, and bladder; heart and spleen showed moderate, declining uptake, only. The biologic half-life in blood was 29 min. Urinary accumulation of (68)Ga-NOTA-UBI29-41 peaked at 3.8 ± 0.91 percentage injected dose per gram (%ID) at 120 min, and 88 ± 5.2 %ID was recovered in total urine. (68)Ga-NOTA-UBI29-41 imaging in (b) selectively visualized the muscular infection site and was differentiated from sterile inflammatory processes. Standardized uptake value ratios for muscles (infected/inflamed) were 2.9 ± 0.93, 2.9 ± 0.50, 3.5 ± 0.86, and 3.8 ± 0.90 at 5, 30, 60, and 90 min after injection, respectively. Rabbit lungs with asthma showed insignificant uptake. CONCLUSION : (68)Ga-NOTA-UBI29-41 was strongly localized in bacteria-infected areas and minimally detected in a sterile inflammation area in rabbit muscles. The findings propose this compound to be an excellent first-line PET/CT tracer to allow the distinguishing of infection from inflammation. | en_US |
dc.description.librarian | hb2014 | en_US |
dc.description.uri | http://jnm.snmjournals.org/ | en_US |
dc.identifier.citation | Ebenhan, T, Zeevaart, JR, Venter, JD, Govender, T, Kruger, GH, Jarvis, NV & Sathekge, MM 2014, 'Preclinical evaluation of 68Ga-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid-ubiquicidin as a radioligand for PET infection imaging', Journal of Nuclear Medicine, vol. 55, no. 2, pp. 308-314. | en_US |
dc.identifier.issn | 0161-5505 (print) | |
dc.identifier.issn | 1535-5667 (online) | |
dc.identifier.other | 10.2967/jnumed.113.128397 | |
dc.identifier.uri | http://hdl.handle.net/2263/41441 | |
dc.language.iso | en | en_US |
dc.publisher | Society of Nuclear Medicine | en_US |
dc.rights | © 2014 Society of Nuclear Medicine and Molecular Imaging. This research was originally published in Journal of Nuclear Medicine, Preclinical evaluation of 68Ga-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid-ubiquicidin as a radioligand for PET infection imaging, Ebenhan, T, Zeevaart, JR, Venter, JD, Govender, T, Kruger, GH, Jarvis, NV & Sathekge, MM, vol. 55, no.2, pp. 308-314, doi : 10.2967/jnumed.113.128397. | en_US |
dc.subject | 68Ga labeling | en_US |
dc.subject | PET/CT | en_US |
dc.subject | UBI29-41 | en_US |
dc.subject | Infection | en_US |
dc.subject | Ubiquicidin | en_US |
dc.subject | Computerized tomography (CT) | |
dc.subject | Positron emission tomography (PET) | |
dc.title | Preclinical evaluation of 68Ga-labeled 1,4,7-triazacyclononane-1,4,7-triacetic acid-ubiquicidin as a radioligand for PET infection imaging | en_US |
dc.type | Postprint Article | en_US |